Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19
23 nov. 2020 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19 Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the...
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
24 oct. 2020 09h45 HE
|
Revolution Medicines, Inc.
Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profiles for RMC-4630 Combined with Cobimetinib and...
L'inclusion du premier patient dans l'essai clinique de Phase 3 avec monalizumab déclenche un paiement de 50M$ d'AstraZeneca
23 oct. 2020 01h00 HE
|
INNATE PHARMA
Ce paiement d’étape renforce la position de trésorerie d’Innate INTERLINK-1 est la première étude de Phase 3 étudiant une approche d’immunothérapie chez des patients présentant un cancer de la tête...
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
23 oct. 2020 01h00 HE
|
INNATE PHARMA
Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy...
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
08 oct. 2020 10h30 HE
|
RedHill Biopharma Ltd.
RedHill obtains Israel rights to Movantik® from AstraZeneca, giving RedHill global rights, excluding Europe and Canada--Movantik approved for opioid-induced constipation in Israel under the brand name...
Agility Key to Post-Pandemic Recovery, ISG Experts Say
30 sept. 2020 08h58 HE
|
Information Services Group, Inc.
STAMFORD, Conn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Leading business thinkers will explore the potential of the agile enterprise and digital operating models to drive success in a post-pandemic...
Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222
01 sept. 2020 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate
28 mai 2020 07h38 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
BrightInsight Announces Global Digital Health Partnership with AstraZeneca
25 mars 2020 08h00 HE
|
BrightInsight
SAN JOSE, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading regulated Internet of Things (IoT) platform for biopharma and medtech, announced today a global...
New global survey shows misperceptions about lung cancer among the general public
27 nov. 2019 02h00 HE
|
Lung Ambition Alliance
LONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Only one in five people (22%) disagree with the statement “generally, patients with lung cancer have caused their illness through their lifestyle choices...